Similarly, although small-molecule KMO inhibitors (such as CHDI-340246) have shown promise in Huntington’s models [45], their ocular bioavailability, safety profile, and efficacy in rodent models of ocular hypertension remain untested. This evidence concerns the gene KMO and ocular hypertension.